- Report
- April 2025
- 50 Pages
Global
From €2502EUR$2,650USD£2,146GBP
Amiphenazole is a respiratory drug used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. It is a long-acting beta-agonist (LABA) that works by relaxing the muscles of the airways, allowing more air to flow in and out of the lungs. It is usually taken in combination with an inhaled corticosteroid (ICS) to reduce inflammation in the airways. Amiphenazole is available in both oral and inhaled forms, and is often prescribed as a maintenance therapy for long-term control of asthma and COPD.
Amiphenazole is a widely used respiratory drug, with many generic and branded versions available on the market. It is typically prescribed as a maintenance therapy for long-term control of asthma and COPD, and is often used in combination with an ICS. Common brands of Amiphenazole include Advair, Symbicort, Dulera, and Breo.
Some companies in the Amiphenazole market include GlaxoSmithKline, AstraZeneca, Merck, and Boehringer Ingelheim. Show Less Read more